Asensus Surgical to Participate in the H.C. Wainwright In-Person BioConnect Investor Conference
Asensus Surgical, Inc. (NYSE American: ASXC) has announced participation in the H.C. Wainwright In-Person Bio-Connect Investor Conference. CEO Anthony Fernando and CFO Shameze Rampertab are set to engage in a fireside chat on May 2, 2023, at 11:30 am ET. Interested parties can access the conference webcast via the company's investor relations page, with replays available for 90 days. Asensus is focused on enhancing surgical outcomes through its innovative Performance-Guided Surgery™ model. The company is developing the LUNA™ Surgical System, building on its Digital Laparoscopy and Senhance® Surgical System. The Senhance system is currently available in several regions including the US, EU, and Japan. For further insights, visit the company's websites.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright In-Person Bio-Connect Investor Conference. The Company’s fireside chat will take place on Tuesday, May 2, 2023 at 11:30 am Eastern Time.
The conference webcast will be available online on the investor relations page of the Company’s website at https://ir.asensus.com/events-and-presentations. Replays of the webcasts will be archived on the website for approximately 90 days.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. Based upon the foundations of Digital Laparoscopy and the Senhance® Surgical System, the Company is developing the LUNA™ Surgical System, a next generation robotic and instrument system as a foundation of its Digital Surgery solution. These systems will be powered by the Intelligent Surgical Unit™ to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. The Senhance Surgical System is now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. To learn more about Performance-Guided Surgery, Digital Laparoscopy with the Senhance Surgical System and the new LUNA System visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/c/transenterix
Vimeo: https://vimeo.com/asxc
TikTok: https://www.tiktok.com/@asensus_surgical
INVESTOR CONTACT:
Mark Klausner or Mike Vallie
ICR Westwicke
invest@asensus.com
443-213-0499
MEDIA CONTACT:
Dan Ventresca
Matter Communications
AsensusPR@matternow.com
617-874-5488
FAQ
When will Asensus Surgical participate in the H.C. Wainwright Bio-Connect Investor Conference?
Who will represent Asensus Surgical at the H.C. Wainwright Conference?
How can I watch the Asensus Surgical conference webcast?
What is the focus of Asensus Surgical's Performance-Guided Surgery?
Where is the Senhance Surgical System available for sale?
